List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7383973/publications.pdf Version: 2024-02-01

247 papers	11,711 citations	25034 57 h-index	³⁸³⁹⁵ 95 g-index
papero		in index	5 mack
271 all docs	271 docs citations	271 times ranked	7391 citing authors

#	Article	IF	CITATIONS
1	Structure and Function of Hemidesmosomes: More Than Simple Adhesion Complexes. Journal of Investigative Dermatology, 1999, 112, 411-418.	0.7	513
2	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. Journal of the American Academy of Dermatology, 2008, 58, 1043-1046.	1.2	464
3	Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, 2012, 66, 479-485.	1.2	294
4	Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. British Journal of Dermatology, 2015, 172, 867-877.	1.5	264
5	Diagnostic delay in hidradenitis suppurativa is a global problem. British Journal of Dermatology, 2015, 173, 1546-1549.	1.5	261
6	Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. British Journal of Dermatology, 2009, 161, 861-868.	1.5	228
7	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology, 2020, 82, 575-585.e1.	1.2	224
8	Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (<scp>EDF</scp>) in cooperation with the European Academy of Dermatology and Venereology (<scp>EADV</scp>). Journal of the European Academy of Dermatology and Venereology, 2015, 29, 405-414.	2.4	218
9	Hemidesmosomes: roles in adhesion, signaling and human diseases. Current Opinion in Cell Biology, 1996, 8, 647-656.	5.4	207
10	Analysis of the interactions between BP180, BP230, plectin and the integrin α6β4 important for hemidesmosome assembly. Journal of Cell Science, 2003, 116, 387-399.	2.0	206
11	Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls Journal of Clinical Investigation, 1998, 102, 2082-2089.	8.2	201
12	Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatology, The, 2021, 3, e789-e797.	3.9	179
13	Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clinical Immunology, 2008, 128, 415-426.	3.2	173
14	Hemidesmosome Formation Is Initiated by the β4 Integrin Subunit, Requires Complex Formation of β4 and HD1/Plectin, and Involves a Direct Interaction between β4 and the Bullous Pemphigoid Antigen 180. Journal of Cell Biology, 1998, 142, 271-284.	5.2	171
15	Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. American Journal of Hematology, 2001, 66, 142-144.	4.1	171
16	Severity and Phenotype of Bullous Pemphigoid Relate to Autoantibody Profile Against the NH2- and COOH-Terminal Regions of the BP180 Ectodomain. Journal of Investigative Dermatology, 2002, 119, 1065-1073.	0.7	166
17	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1900-1913.	2.4	159
18	Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. Clinical Reviews in Allergy and Immunology, 2018, 54, 26-51.	6.5	158

#	Article	IF	CITATIONS
19	Recommendations for the use of rituximab (antiâ€CD20 antibody) in the treatment of autoimmune bullous skin diseases [§] . JDDG - Journal of the German Society of Dermatology, 2008, 6, 366-373.	0.8	144
20	Definitions and outcome measures for mucous membrane pemphigoid: Recommendations ofÂanÂinternational panel of experts. Journal of the American Academy of Dermatology, 2015, 72, 168-174.	1.2	133
21	Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: Results of a Prospective Multicenter Study. Journal of Investigative Dermatology, 2011, 131, 2271-2280.	0.7	132
22	Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. Journal of the American Academy of Dermatology, 2018, 78, 1090-1096.	1.2	127
23	Bullous pemphigoid: From the clinic to the bench. Clinics in Dermatology, 2012, 30, 3-16.	1.6	123
24	The Localization of Bullous Pemphigoid Antigen 180 (BP180) in Hemidesmosomes Is Mediated by Its Cytoplasmic Domain and Seems to be Regulated by the β4 Integrin Subunit. Journal of Cell Biology, 1997, 136, 1333-1347.	5.2	121
25	BP230- and BP180-specific Auto-Antibodies in Bullous Pemphigoid. Journal of Investigative Dermatology, 2004, 122, 1413-1422.	0.7	118
26	The Z-disc proteins myotilin and FATZ-1 interact with each other and are connected to the sarcolemma via muscle-specific filamins. Journal of Cell Science, 2005, 118, 3739-3749.	2.0	115
27	Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. British Journal of Dermatology, 2016, 175, 1382-1386.	1.5	112
28	Autoreactive T and B Cells from Bullous Pemphigoid (BP) Patients Recognize Epitopes Clustered in Distinct Regions of BP180 and BP230. Journal of Immunology, 2006, 176, 2015-2023.	0.8	110
29	IgG Autoantibodies from Bullous Pemphigoid (BP) Patients Bind Antigenic Sites on Both the Extracellular and the Intracellular Domains of the BP Antigen 180. Journal of Investigative Dermatology, 1999, 112, 141-147.	0.7	106
30	Plakins, a Versatile Family of Cytolinkers: Roles in Skin Integrity and in Human Diseases. Journal of Investigative Dermatology, 2014, 134, 885-894.	0.7	103
31	Bullous Pemphigoid: Physiopathology, Clinical Features and Management. Advances in Dermatology, 2007, 23, 257-288.	2.0	101
32	Respective Contribution of Neutrophil Elastase and Matrix Metalloproteinase 9 in the Degradation of BP180 (Type XVII Collagen) in Human Bullous Pemphigoid. Journal of Investigative Dermatology, 2001, 117, 1091-1096.	0.7	100
33	The Extracellular Domain of BPAC2 Localizes to Anchoring Filaments and its Carboxyl Terminus Extends to the Lamina Densa of Normal Human Epidermal Basement Membrane. Journal of Investigative Dermatology, 1997, 109, 200-206.	0.7	99
34	Clinical Features and Practical Diagnosis of Bullous Pemphigoid. Dermatologic Clinics, 2011, 29, 427-438.	1.7	99
35	Interaction of the Bullous Pemphigoid Antigen 1 (BP230) and Desmoplakin with Intermediate Filaments Is Mediated by Distinct Sequences within Their COOH Terminus. Molecular Biology of the Cell, 2003, 14, 1978-1992.	2.1	98
36	The Protease Inhibitor Alpha-2-Macroglobuline-Like-1 Is the p170 Antigen Recognized by Paraneoplastic Pemphigus Autoantibodies in Human. PLoS ONE, 2010, 5, e12250.	2.5	98

#	Article	IF	CITATIONS
37	IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. British Journal of Dermatology, 2000, 143, 349-355.	1.5	96
38	Laboratory diagnosis of paraneoplastic pemphigus. British Journal of Dermatology, 2013, 169, 1016-1024.	1.5	94
39	Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Archives of Dermatology, 2001, 137, 269-72.	1.4	92
40	Characterization of the Anti-BP180 Autoantibody Reactivity Profile and Epitope Mapping in Bullous Pemphigoid Patients11Tables 1, 2, 3 and 5 can be found at http://www.blackwellpublishing.com/products/journals/suppmat/jid/jid22126/jid22126sm.htm. Journal of Investigative Dermatology, 2004, 122, 103-110.	0.7	89
41	Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. British Journal of Dermatology, 2012, 167, 1111-1117.	1.5	86
42	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1926-1948.	2.4	86
43	IgG Autoantibodies from Bullous Pemphigoid Patients Recognize Multiple Antigenic Reactive Sites Located Predominantly Within the B and C Subdomains of the COOH-Terminus of BP230. Journal of Investigative Dermatology, 2000, 114, 998-1004.	0.7	85
44	Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1105-1113.	5.7	85
45	The Cutaneous Spectrum of Lupus Erythematosus. Clinical Reviews in Allergy and Immunology, 2017, 53, 291-305.	6.5	83
46	Mortality of bullous pemphigoid in Switzerland: a prospective study. British Journal of Dermatology, 2011, 165, 368-374.	1.5	80
47	One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1. Experimental Dermatology, 2016, 25, 10-16.	2.9	80
48	Gender and age significantly determine patient needs and treatment goals in psoriasis $\hat{a} \in $ a lesson for practice. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 700-708.	2.4	78
49	Urticarial vasculitis associated with a monoclonal IgM gammopathy: Schnitzler's syndrome. British Journal of Dermatology, 1990, 123, 113-118.	1.5	75
50	lgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris. British Journal of Dermatology, 2001, 144, 1183-1188.	1.5	75
51	Human "T _H 9―cells are a subpopulation of PPAR-γ ⁺ T _H 2 cells. Science Immunology, 2019, 4, .	11.9	75
52	The Hemidesmosomal Protein Bullous Pemphigoid Antigen 1 and the Integrin β4 Subunit Bind to ERBIN. Journal of Biological Chemistry, 2001, 276, 32427-32436.	3.4	73
53	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1750-1764.	2.4	72
54	Shedding of Collagen XVII/BP180. Journal of Biological Chemistry, 2004, 279, 24521-24529.	3.4	71

#	ARTICLE Calculation of cutâ€off values based on the Autoimmune Bullous Skin Disorder Intensity Score () Tj ETQq1 1 0.7	IF 84314 rgB ⁻	CITATIONS
55	for defining moderate, significant and extensive types of pemphigus. British Journal of Dermatology, 2016, 175, 142-149.	1.5	68
56	Immune response in pemphigus and beyond: progresses and emerging concepts. Seminars in Immunopathology, 2016, 38, 57-74.	6.1	68
57	Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clinical Immunology, 2010, 134, 320-330.	3.2	64
58	Updated <scp>S2</scp> K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>). Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1689-1704.	2.4	61
59	Role of the Bullous Pemphigoid Antigen 180 (BP180) in the Assembly of Hemidesmosomes and Cell Adhesion—Reexpression of BP180 in Generalized Atrophic Benign Epidermolysis Bullosa Keratinocytes. Experimental Cell Research, 1998, 239, 463-476.	2.6	59
60	New insights into the molecular basis of desmoplakinand desmin-related cardiomyopathies. Journal of Cell Science, 2006, 119, 4974-4985.	2.0	57
61	Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis?. British Journal of Dermatology, 2005, 152, 537-540.	1.5	55
62	Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis. British Journal of Dermatology, 2011, 165, 1133-1137.	1.5	55
63	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. Journal of Investigative Dermatology, 2019, 139, 31-37.	0.7	55
64	Autoantibodies from a Patient with Paraneoplastic Pemphigus Bind Periplakin, a Novel Member of the Plakin Family. Journal of Investigative Dermatology, 1998, 111, 338-340.	0.7	51
65	Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. British Journal of Dermatology, 2001, 144, 760-768.	1.5	49
66	Erosive pustular dermatosis of the leg: report of three cases. British Journal of Dermatology, 2002, 147, 765-769.	1.5	47
67	Rituximab Immunotherapy in Pemphigus: Therapeutic Effects Beyond B-Cell Depletion. Journal of Investigative Dermatology, 2008, 128, 2745-2747.	0.7	47
68	Anti-Alpha-2-Macroglobulin-Like-1 Autoantibodies Are Detected Frequently and May Be Pathogenic in Paraneoplastic Pemphigus. Journal of Investigative Dermatology, 2013, 133, 1785-1793.	0.7	47
69	Childhood bullous pemphigoid: Report of a case with characterization of the targeted antigens. Journal of the American Academy of Dermatology, 1999, 40, 338-344.	1.2	46
70	Pyogenic granuloma-like lesions during capecitabine therapy. British Journal of Dermatology, 2002, 147, 1270-1272.	1.5	46
71	Deletion of the Cytoplasmatic Domain of BP180/Collagen XVII Causes a Phenotype with Predominant Features of Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2002, 118, 185-192.	0.7	45
72	EpiDex® Swiss Field Trial 2004–2008. Dermatology, 2010, 221, 365-372.	2.1	45

#	Article	IF	CITATIONS
73	Canakinumab for Severe Hidradenitis Suppurativa. JAMA Dermatology, 2017, 153, 1195.	4.1	45
74	Homozygous Missense Mutation in <i>IL36RN</i> in Generalized Pustular Dermatosis With Intraoral Involvement Compatible With Both AGEP and Generalized Pustular Psoriasis. JAMA Dermatology, 2015, 151, 452.	4.1	44
75	Mepolizumab failed to affect bullous pemphigoid: A randomized, placeboâ€controlled, doubleâ€blind phase 2 pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 669-672.	5.7	44
76	Skin manifestations of cardio-facio-cutaneous syndrome. Journal of the American Academy of Dermatology, 1993, 28, 815-819.	1.2	43
77	Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd: <scp>YAG</scp> laser: a prospective, comparative, randomized, openâ€label trial. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 549-554.	2.4	43
78	Multiple cutaneous osteomas of the face associated with chronic inflammatory acne. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 321-326.	2.4	42
79	Plectin interacts with the rod domain of type III intermediate filament proteins desmin and vimentin. European Journal of Cell Biology, 2011, 90, 390-400.	3.6	42
80	Takayasu Arteritis and Cutaneous Necrotizing Vasculitis. Dermatology, 2000, 200, 139-143.	2.1	41
81	Childhood Bullous Pemphigoid: Report of a Case with Life-Threatening Course During Homeopathy Treatment. Pediatric Dermatology, 2004, 21, 160-163.	0.9	40
82	Giant Cellulitis-like Sweet Syndrome, a New Variant of Neutrophilic Dermatosis. JAMA Dermatology, 2013, 149, 79.	4.1	40
83	Monocytes enhance neutrophilâ€induced blister formation in an ex vivo model of bullous pemphigoid. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1119-1130.	5.7	40
84	Penicilliosis marneffei infection in AIDS. Journal of the American Academy of Dermatology, 1994, 31, 843-846.	1.2	39
85	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology, 2016, 232, 385-406.	2.1	39
86	Facial Basal Cell Carcinomas Recurring after Photodynamic Therapy: A Retrospective Analysis of Histological Subtypes. Dermatology, 2012, 224, 346-351.	2.1	38
87	A Case of Amicrobial Pustulosis of the Folds Associated with Neutrophilic Gastrointestinal Involvement in Systemic Lupus Erythematosus. Dermatology, 2005, 211, 356-359.	2.1	37
88	Mucocutaneous Lichen Planus With Esophageal Involvement. Archives of Dermatology, 2008, 144, 1427.	1.4	37
89	The subcellular distribution of the high molecular mass protein, HD1, is determined by the cytoplasmic domain of the integrin β4 subunit. Journal of Cell Science, 1997, 110, 169-178.	2.0	37
90	Localized pretibial pemphigoid and pemphigoid nodularis. Journal of the American Academy of Dermatology, 1992, 27, 863-867.	1.2	36

#	Article	IF	CITATIONS
91	Focal Palmoplantar Keratoderma Caused by an Autosomal Dominant Inherited Mutation in the Desmoglein 1 Gene. Dermatology, 2006, 212, 117-122.	2.1	36
92	Oral intraepidermal IgA pustulosis and Crohn's disease. British Journal of Dermatology, 1992, 126, 383-386.	1.5	35
93	Drug-induced epidermolysis bullosa acquisita with antibodies to type VII collagen. Journal of the American Academy of Dermatology, 2002, 46, S161-S164.	1.2	35
94	Interaction of Plectin with Keratins 5 and 14: Dependence on Several Plectin Domains and Keratin Quaternary Structure. Journal of Investigative Dermatology, 2014, 134, 2776-2783.	0.7	35
95	Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?. Current Opinion in Oncology, 2017, 29, 129-135.	2.4	35
96	Mortality Rate in Bullous Pemphigoid: A Retrospective Monocentric Cohort Study. Dermatology, 2012, 225, 320-325.	2.1	34
97	Medical, psychological and socioâ€economic implications of chronic hand eczema: a crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 628-637.	2.4	34
98	Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. Journal of Investigative Dermatology, 2017, 137, 1199-1203.	0.7	34
99	Evidence-Based Management of Bullous Pemphigoid. Dermatologic Clinics, 2011, 29, 613-620.	1.7	33
100	Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Frontiers in Immunology, 2020, 11, 611549.	4.8	33
101	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. Dermatology, 2016, 232, 640-647.	2.1	32
102	Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center. Journal of the American Academy of Dermatology, 2018, 78, 806-808.	1.2	32
103	Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid. Frontiers in Immunology, 2019, 10, 1919.	4.8	32
104	Acute pustulosis of the legs in diverticulitis with sigmoid stenosis: an overlap between bowelâ€associated dermatosis–arthritis syndrome and pustular pyoderma gangrenosum. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 89-92.	2.4	31
105	Value of a Novel Neisseria Meningitidis–Specific Polymerase Chain Reaction Assay in Skin Biopsy Specimens as a Diagnostic Tool in Chronic Meningococcemia. Archives of Dermatology, 2008, 144, 770-3.	1.4	31
106	Acral Persistent Papular Mucinosis and IgA Monoclonal Gammopathy: Report of a Case. Dermatology, 1992, 185, 134-136.	2.1	30
107	Amicrobial Pustulosis-Like Rash in a Patient with Crohn's Disease under Anti-TNF-Alpha Blocker. Dermatology, 2011, 222, 304-310.	2.1	30
108	Systemic Light-Chain Amyloidosis Revealed by Progressive Nail Involvement, Diffuse Alopecia and Sicca Syndrome: Report of an Unusual Case with a Review of the Literature. Dermatology, 2014, 228, 97-102.	2.1	30

#	Article	IF	CITATIONS
109	Bowen disease of the nail unit: a retrospective study of 12 cases and their association with human papillomaviruses. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1503-1506.	2.4	30
110	Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid. Dermatology, 2017, 233, 401-403.	2.1	30
111	Reverse Phenotyping in Patients with Skin Capillary Malformations and Mosaic GNAQ or GNA11 Mutations Defines a Clinical Spectrum with Genotype-Phenotype Correlation. Journal of Investigative Dermatology, 2020, 140, 1106-1110.e2.	0.7	30
112	Diagnostic value of an enzyme-linked immunosorbent assay using BP180 recombinant proteins in elderly patients with pruritic skin disorders. British Journal of Dermatology, 2003, 149, 910-912.	1.5	29
113	Calcifying panniculitis following subcutaneous injections of nadroparin-calcium in a patient with osteomalacia. British Journal of Dermatology, 2005, 153, 657-660.	1.5	29
114	Eosinophils as putative therapeutic targets in bullous pemphigoid. Experimental Dermatology, 2017, 26, 1187-1192.	2.9	29
115	Phosphorylation of serine 4642 in the COOH-extremity of plectin by MNK2 and PKA modulates its interaction with intermediate filaments. Journal of Cell Science, 2013, 126, 4195-207.	2.0	28
116	Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis. European Journal of Dermatology, 2018, 28, 287-313.	0.6	28
117	An unusual form of primary systemic amyloidosis: amyloid elastosis: report of a case treated by haematopoietic cell transplantation. British Journal of Dermatology, 2003, 148, 154-159.	1.5	27
118	Localized Childhood Vulval Pemphigoid Treated with Tacrolimus Ointment. Dermatology, 2004, 208, 273-275.	2.1	27
119	BPAC1a and b Associate with EB1 and EB3 and Modulate Vesicular Transport, Golgi Apparatus Structure, and Cell Migration in C2.7 Myoblasts. PLoS ONE, 2014, 9, e107535.	2.5	27
120	Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e256-e257.	2.4	27
121	Genomic Organization of the Mouse β1 Gene: Conservation of the β1D but not of the β1B and β1C Integrin Splice Variants. Cell Adhesion and Communication, 1996, 4, 1-11.	1.7	26
122	Treatment of primary anetoderma with colchicine. Journal of the American Academy of Dermatology, 1998, 38, 1002-1003.	1.2	26
123	Anti-glomerular basement membrane nephritis and bullous pemphigoid caused by distinct anti-α3(IV)NC1 and anti-BP180 antibodies in a patient with Crohn's disease. American Journal of Kidney Diseases, 2002, 40, 649-654.	1.9	26
124	IgG Autoantibodies from a Lichen planus pemphigoides Patient Recognize the NC16A Domain of the Bullous Pemphigoid Antigen 180. Dermatology, 1999, 199, 253-255.	2.1	25
125	BPAG1 isoform-b: Complex distribution pattern in striated and heart muscle and association with plectin and α-actinin. Experimental Cell Research, 2010, 316, 297-313.	2.6	25
126	Acral Purpura as Leading Clinical Manifestation of Dermatitis Herpetiformis: Report of Two Adult Cases with a Review of the Literature. Dermatology, 2013, 227, 1-4.	2.1	25

#	Article	lF	CITATIONS
127	The expanding spectrum of clinical phenotypes associated with <i>PSTPIP1</i> mutations: from PAPA to PAMI syndrome and beyond. British Journal of Dermatology, 2018, 178, 982-983.	1.5	25
128	Distinct interferonâ€gamma and interleukinâ€9 expression in cutaneous and oral lichen planus. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 880-886.	2.4	23
129	Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease. Frontiers in Immunology, 2021, 12, 800149.	4.8	23
130	Plectin, an unusual target antigen in bullous pemphigoid. British Journal of Dermatology, 2001, 144, 136-138.	1.5	22
131	Molecular Consequences of Deletion of the Cytoplasmic Domain of Bullous Pemphigoid 180 in a Patient with Predominant Features of Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2004, 122, 65-72.	0.7	22
132	Comparative analysis of the expression of ERBIN and Erb-B2 in normal human skin and cutaneous carcinomas British Journal of Dermatology, 2005, 152, 1248-1255.	1.5	22
133	Chronic Hemicorporal Prurigo Related to a Posttraumatic Brown-Séquard Syndrome. Dermatology, 2008, 217, 45-47.	2.1	22
134	Patterns of chronic hand eczema: a semantic map analysis of the <scp>CARPE</scp> registry data. British Journal of Dermatology, 2018, 178, 229-237.	1.5	22
135	The evolving field of Dermatoâ€oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2183-2197.	2.4	22
136	Combined complete C5 and partial C4 deficiency in humans: Clinical consequences and complement-mediated functions in vitro. Clinical Immunology and Immunopathology, 1990, 55, 41-55.	2.0	21
137	In Vitro Methods for Investigating Desmoplakin–Intermediate Filament Interactions and Their Role in Adhesive Strength. Methods in Cell Biology, 2004, 78, 757-786.	1.1	21
138	Multiple Hyperkeratotic Spicules and Myeloma. Dermatology, 2002, 205, 210-212.	2.1	20
139	Diagnostic value of immunohistochemistry on formalin-fixed, paraffin-embedded skin biopsy specimens for bullous pemphigoid. British Journal of Dermatology, 2016, 175, 988-993.	1.5	20
140	Pemphigoid nodularis. Archives of Dermatology, 1990, 126, 1522-1523.	1.4	20
141	Acquired Melanocytic Naevus in Childhood Vulval Pemphigoid. Dermatology, 2006, 213, 159-162.	2.1	19
142	Metastatic Eccrine Sweat Gland Carcinoma: Case Report. Dermatology, 1988, 177, 295-299.	2.1	18
143	Mycetoma of the Foot due to <i>Fusarium </i> sp. Treated with Oral Ketoconazole. Dermatology, 1992, 184, 303-305.	2.1	18
144	â€~Bullous' Pemphigoid: What Are You? Urgent Need of Definitions and Diagnostic Criteria. Dermatology, 2010, 221, 131-134.	2.1	18

#	Article	IF	CITATIONS
145	Efficacy of topical tacrolimus for oral lichen planus: realâ€life experience in a retrospective cohort of patients with a review of the literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1107-1113.	2.4	18
146	Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e112-e115.	2.4	18
147	Mutations in <i><scp>POGLUT</scp>1</i> in Galli–Galli/Dowling–Degos disease. British Journal of Dermatology, 2017, 176, 270-274.	1.5	17
148	A recessive mutation in the <i>DSP</i> gene linked to cardiomyopathy, skin fragility and hair defects impairs the binding of desmoplakin to epidermal keratins and the muscle-specific intermediate filament desmin. British Journal of Dermatology, 2018, 179, 797-799.	1.5	17
149	Hereditary Angioedema and Oral Contraception. Dermatology, 1990, 181, 78-79.	2.1	16
150	Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus?. Dermatology, 2007, 214, 275-277.	2.1	16
151	Primary Atrophic Solitary Morphea Profunda. Dermatology, 2008, 217, 207-210.	2.1	16
152	Oral Mucous Membrane Pemphigoid: Complete Response to Topical Tacrolimus. Acta Dermato-Venereologica, 2011, 91, 604-605.	1.3	16
153	Oral lichen planus and oral lichenoid lesions – an analysis of clinical and histopathological features. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e104-e107.	2.4	15
154	Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid. JAMA Dermatology, 2021, 157, 421.	4.1	15
155	Ultraviolet radiation protection and skin cancer awareness in recreational athletes: a survey among participants in a running event. Swiss Medical Weekly, 2016, 146, w14297.	1.6	15
156	Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy. RMD Open, 2022, 8, e002166.	3.8	15
157	Schonlein-Henoch purpura associated with losartan treatment and presence of antineutrophil cytoplasmic antibodies of x specificity. British Journal of Dermatology, 2001, 145, 362-363.	1.5	14
158	Specific Nail Alterations in Cutaneous T-Cell Lymphoma. Archives of Dermatology, 2010, 146, 1287-91.	1.4	14
159	Chronic hand eczema: A prospective analysis of the Swiss CARPE registry focusing on factors associated with clinical and quality of life improvement. Contact Dermatitis, 2018, 79, 136-148.	1.4	14
160	Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms. Frontiers in Immunology, 0, 13, .	4.8	14
161	A rare tumour of the nail apparatus: onychomatricoma. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1127-1128.	2.4	13
162	Oral Mucosal Morphea: A New Variant. Dermatology, 2012, 224, 215-220.	2.1	13

#	Article	IF	CITATIONS
163	Cutaneous Collagenous Vasculopathy: A Rare Form of Microangiopathy Successfully Treated with a Combination of Multiplex Laser and Optimized Pulsed Light with a Review of the Literature. Dermatology, 2016, 232, 107-111.	2.1	13
164	Mucous membrane pemphigoid of the oral lichen type: a retrospective analysis of 16 cases. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e205-e207.	2.4	13
165	Cutaneous Reactive Angiomatosis with Combined Histological Pattern Mimicking a Cellulitis. Dermatology, 2013, 227, 226-230.	2.1	13
166	PAPULAR-PURPURIC "GLOVES AND SOCKS" SYNDROME. International Journal of Dermatology, 1994, 33, 196-197.	1.0	12
167	Clinical significance of platelet-associated immunoglobulins in narcotic addicts with human immunodeficiency virus infection. Clinical Immunology and Immunopathology, 1990, 54, 256-265.	2.0	11
168	Endemic Pemphigus Foliaceus: Towards Understanding Autoimmune Mechanisms of Disease Development. Journal of Investigative Dermatology, 2012, 132, 2499-2502.	0.7	11
169	Desmoplakin Gene Variants and Risk for Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002241.	3.6	11
170	Bullous colon lesions in a patient with bullous pemphigoid. Gastrointestinal Endoscopy, 2001, 54, 104-108.	1.0	10
171	Linear sclerodermic lupus erythematosus, a distinct variant of linear morphea and chronic cutaneous lupus erythematous. International Journal of Dermatology, 2011, 50, 1491-1495.	1.0	10
172	Autoimmune Progesterone Dermatitis: Potential Role of Cutaneous Angiogenin Expression?. Dermatology, 2011, 223, 32-35.	2.1	10
173	Toward a Practical Renaming of Bullous Pemphigoid and All Its Variants. JAMA Dermatology, 2014, 150, 459.	4.1	10
174	Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management. Drugs and Aging, 2016, 33, 711-723.	2.7	10
175	Development of pemphigus vulgaris following mRNA SARSâ€CoVâ€19 BNT162b2 vaccination in an 89â€yearâ€o patient. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	ld _{2.4}	10
176	Subungual Exostosis. New England Journal of Medicine, 2008, 359, e31.	27.0	9
177	Rituximab for Severe Mucous Membrane Pemphigoid. Archives of Dermatology, 2011, 147, 855.	1.4	9
178	A New Light on an Old Disease: Adhesion Signaling in Pemphigus Vulgaris. Journal of Investigative Dermatology, 2014, 134, 8-10.	0.7	9
179	Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid. Journal of Ophthalmic Inflammation and Infection, 2018, 8, 12.	2.2	9
180	Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice. Archives of Dermatology, 1995, 131, 590-5.	1.4	9

LUCA BORRADORI

#	Article	lF	CITATIONS
181	Acute Genitocrural Intertrigo: A Sign of Primary Human Immunodeficiency Virus Type 1 Infection. Dermatology, 2001, 203, 171-173.	2.1	8
182	Red fingers syndrome associated with hepatitis C virus. Journal of the European Academy of Dermatology and Venereology, 2002, 16, 187-188.	2.4	8
183	Widespread skin necrosis associated with unfractionated heparin therapy in a patient under chronic coumarin anticoagulation. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 327-330.	2.4	8
184	A tattoo complicated by allergic contact dermatitis and panniculitis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 127-128.	2.4	8
185	Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib. Case Reports in Dermatology, 2014, 6, 213-217.	0.8	8
186	Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e129-e131.	2.4	8
187	Evidence for a New Fumarate Hydratase Gene Mutation in a Unilateral Type 2 Segmental Leiomyomatosis. Dermatology, 2010, 221, 149-153.	2.1	7
188	Late secondary syphilis with nodular lesions mimicking Kaposi sarcoma in a patient with human immunodeficiency virus. International Journal of Dermatology, 2014, 53, e71-e73.	1.0	7
189	Effects of Systematic Patient Education in Skin Care and Protection in a Hand Eczema Clinic. Dermatology, 2014, 228, 220-224.	2.1	7
190	Prurigo Pigmentosa in White Monozygotic Twins. JAMA Dermatology, 2017, 153, 353.	4.1	7
191	The pathogenesis of pemphigus: Controversy vs complexity. Experimental Dermatology, 2017, 26, 1271-1273.	2.9	7
192	Herpes zoster of the trigeminal nerve with multi-dermatomal involvement: a case report of an unusual presentation. BMC Dermatology, 2020, 20, 12.	2.1	7
193	Relative importance of total versus external platelet-associated IgG. Blut, 1989, 59, 67-74.	1.2	6
194	Bullous Systemic Lupus erythematosus. Dermatology, 1993, 187, 306-308.	2.1	6
195	Interaction of BP180 and $\hat{I}\pm\hat{I}^2$ 4. Journal of Investigative Dermatology, 1999, 112, 830-831.	0.7	6
196	Hairy Pinnae after Orchiectomy and Chemotherapy for Testicular Cancer: Acquired Localized Hypertrichosis of the Ears. Dermatology, 2011, 222, 289-291.	2.1	6
197	Development of a Novel Green Fluorescent Protein-Based Binding Assay to Study the Association of Plakins with Intermediate Filament Proteins. Methods in Enzymology, 2016, 569, 117-137.	1.0	6
198	Rituximab for the Treatment of Isolated Refractory Desquamative Gingivitis Due to Mucous Membrane Pemphigoid. JAMA Dermatology, 2016, 152, 1396.	4.1	6

#	Article	IF	CITATIONS
199	Emergency Consultations in Dermatology in a Secondary Referral Hospital in Southern Switzerland: A Prospective Cross-Sectional Analysis. Dermatology, 2019, 235, 243-249.	2.1	6
200	Detection of autoantibodies against alpha-2-macroglobulin-like 1 in paraneoplastic pemphigus sera utilizing novel green fluorescent protein-based immunoassays. Journal of Dermatological Science, 2020, 98, 173-178.	1.9	6
201	Neutrophilic dermatoses with unusual and atypical presentations. Clinics in Dermatology, 2021, 39, 261-270.	1.6	6
202	Linear IgA bullous dermatosis mimicking a neutrophilic dermatosis. European Journal of Dermatology, 2012, 22, 713-714.	0.6	5
203	Severe cutaneous allergic reactions following topical antifungal therapy. Contact Dermatitis, 2013, 68, 56-57.	1.4	5
204	Glucocorticoids in Autoimmune Bullous Diseases: Are Neutrophils the Key Cellular Target?. Journal of Investigative Dermatology, 2013, 133, 2314-2315.	0.7	5
205	Subcutaneous Injection of Large Volumes of Polidocanol. Dermatologic Surgery, 2019, 45, 476-477.	0.8	5
206	Prioritizing topics in guideline development: results of a twoâ€phase online survey of dermatologist members of the <scp>EADV</scp> . Journal of the European Academy of Dermatology and Venereology, 2019, 33, 227-233.	2.4	5
207	Brunsting-Perry pemphigoid: A retrospective case series of a frequently unrecognized condition. Journal of the American Academy of Dermatology, 2021, 85, 1324-1326.	1.2	5
208	Neutrophilic dermatosis of the dorsal hands triggered by mechanical trauma. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e20-e21.	2.4	5
209	Patterns among Patients with Chronic Pruritus: A Retrospective Analysis of 170 Patients. Acta Dermato-Venereologica, 2020, 100, adv00068.	1.3	5
210	Orodigital Pemphigus Vulgaris: A Pathogenic Role of Anti-Desmoglein-3 Autoantibodies in Pemphigus Paronychia?. Dermatology, 2008, 217, 337-339.	2.1	4
211	Bullous Pemphigoid: Simple Measures for a Complex Disease. Journal of Investigative Dermatology, 2012, 132, 1948-1950.	0.7	4
212	Penile Erosions as First Manifestation of Pemphigus Vulgaris: A Misleading Presentation. Acta Dermato-Venereologica, 2013, 93, 248-249.	1.3	4
213	Treatment of sporadic portâ€wine stains: a retrospective review of 17 cases consecutively treated by pulsed sequential dual wavelength 595 and 1064 nm laser. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 557-563.	2.4	4
214	Desmoplakin interacts with the coil 1 of different types of intermediate filament proteins and displays high affinity for assembled intermediate filaments. PLoS ONE, 2018, 13, e0205038.	2.5	4
215	Prurigo Pigmentosa: Demographics and Characteristics in 14 Caucasian Patients. Dermatology, 2021, 237, 878-883.	2.1	4
216	New onset of sarcoidosis after <scp>COVID</scp> â€19 infection. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	4

#	Article	IF	CITATIONS
217	Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid. Antibodies, 2022, 11, 44.	2.5	4
218	Influence of Exogenous Interleukin-2 on the Proliferation of Lymphocytes from Normal Donors and from Patients after Autologous Bone Marrow Transplantation. Acta Haematologica, 1987, 77, 129-134.	1.4	3
219	Simultaneous manifestation of variegate porphyria in monozygotic twins. British Journal of Dermatology, 2008, 159, 503-505.	1.5	3
220	Sensitivity of Immunofluorescence Studies vs Enzyme-Linked Immunosorbent Assay for Diagnosis of Bullous Pemphigoid. Archives of Dermatology, 2011, 147, 1454.	1.4	3
221	Clinical challenges and recent advances in the diagnosis of bullous pemphigoid. Expert Review of Dermatology, 2013, 8, 407-416.	0.3	3
222	Plantar Erythema nodosum in a Patient with Crohnâ€~̃s Disease. Dermatology, 1999, 199, 190-190.	2.1	2
223	Production of the bullous pemphigoid antigen 230 (BP230) by Saccharomyces cerevisiae and Pichia pastoris. Protein Expression and Purification, 2003, 29, 141-147.	1.3	2
224	Re: risk of malignancy and systemic absorption after application of topical tacrolimus in oral lichen planus. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e85-e86.	2.4	2
225	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2313-2318.	2.4	2
226	Pushing and loss of elastic fibers are highly specific for melanoma and rare in melanocytic nevi. Archives of Dermatological Research, 2019, 311, 99-107.	1.9	2
227	Diagnostic performance of direct immunofluorescence microscopy studies by biopsy sites in autoimmune subepidermal blistering dermatoses: a prospective study. British Journal of Dermatology, 2020, 183, 970-972.	1.5	2
228	Pterygium in bullous pemphigoid: An unusual complication. JAAD Case Reports, 2020, 6, 737-739.	0.8	2
229	A relapsing localized variant of neutrophilic dermatosis triggered by tissue injury. British Journal of Dermatology, 2021, 184, 162-164.	1.5	2
230	How to diagnose bullous pemphigoid and its variants: the question is still open. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e434-e435.	2.4	2
231	Comorbidities in lichen planus by phenomeâ€wide association study in two biobank population cohorts. British Journal of Dermatology, 0, , .	1.5	2
232	Annular bullous eruption in a patient with the CREST syndrome, primary biliary cirrhosis, and Sjögren's syndrome. Journal of the American Academy of Dermatology, 1993, 29, 648-650.	1.2	1
233	Bullous pemphigoid: therapeutic algorithm and practical management. Expert Opinion on Orphan Drugs, 2013, 1, 405-412.	0.8	1
234	Acute peripheral unilateral facial nerve paralysis following minor surgery. European Journal of Dermatology, 2014, 24, 417-418.	0.6	1

#	Article	IF	CITATIONS
235	Scarring and chronic ulceration of the floor of the mouth. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 117, 267-271.	0.4	1
236	Cutaneous reactive angiomatosis with foreign body reaction after total knee replacement with a defective implant: a diagnostic challenge with a review of the literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1029-1032.	2.4	1
237	Erythrodermic Epidermolysis Bullosa Acquisita. JAMA Dermatology, 2015, 151, 678.	4.1	1

238 Superficial Neutrophilic Dermatoses: From Subcorneal Pustular Dermatosis (Sneddon-Wilkinson) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6

239	Factors influencing sessions' and speakers' evaluation: an analysis of seven consecutive European Academy of Dermatology and Venereology congress editions. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2307-2313.	2.4	1
240	Herpetiform aphthous ulcerations induced by secukinumab: Report of 2 cases. JAAD Case Reports, 2020, 6, 1107-1109.	0.8	1
241	Bullous Pemphigoid: Clinical Features, Diagnostic Markers, and Immunopathogenic Mechanisms. , 2011, , 65-95.		1
242	Docetaxel-induziertes Rezidiv eines subakuten kutanen Lupus erythematodes und eines Chilblain-Lupus. JDDG - Journal of the German Society of Dermatology, 2013, 11, 871-874.	0.8	0
243	Management of facial papular elastosis by a new generation of dualâ€mode erbium: yttrium aluminium garnet (Er–YAG) laser: report of a case. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e1-e2.	2.4	0
244	Reply to: "Bullous pemphigoid and diabetes mellitus: Are we missing the larger picture?― Journal of the American Academy of Dermatology, 2018, 79, e29-e30.	1.2	0
245	006 TGF-β- and IL-4-induced PPAR-γ promotes IL-9 expression in human TH2 cells. Journal of Investigative Dermatology, 2018, 138, S1.	0.7	0
246	Ulceration and Alopecia of the Scalp Owing to C2 Radiculoneuropathy Following Posterior Atlanto-Axial Fixation. JAMA Dermatology, 2019, 155, 981.	4.1	0
247	lgM autoantibodies to 180- and 230- to 240-kd human epidermal proteins in pregnancy. Archives of Dermatology, 1995, 131, 43-7.	1.4	0